- Rentschler Biopharma SE has celebrated progress on its new buffer media station at its Laupheim headquarters, the company’s largest single investment at the German site.
- The facility, scheduled to be operational by 2028, will enhance automation, digitalisation, and capacity for buffer and media solutions, supporting the company’s CDMO services.
Rentschler Biopharma SE marked the progress of its new buffer media station at its Laupheim headquarters with a time capsule ceremony and panel discussion on October 10, 2025. The project represents the largest single investment in the company’s history at the German site and reflects the company’s focus on strengthening its competitiveness and infrastructure for biopharmaceutical production.
The time capsule, bearing the message “Together We Build,” symbolises Rentschler Biopharma’s commitment to scientific and technological progress. It contains a sample of current buffer and media solutions, a rendering of the new building, messages from site leadership in Laupheim and Milford, and the company’s core values. A panel discussion addressed the attractiveness of Germany as a biotech hub and the role of partnerships in enhancing innovation and supply reliability.
Scheduled to be operational by 2028, the 3,400-square-metre, four-story facility will provide enhanced automation, digitalisation, and additional capacity for buffer and media solutions. It will meet the highest automation and quality standards and contribute to environmental and sustainability goals. The station will feature three media tanks, six buffer tanks, and dedicated areas to comply with strict hygiene and safety requirements, fully integrated with in-house logistics and existing upstream and downstream processes.
“At Rentschler Biopharma, we invest with foresight in infrastructure that ensures stability and sustainable growth – always keeping in mind our clients and, above all, patients worldwide. The new buffer media station marks an important milestone in this regard and, as the largest single investment in our history at our headquarters, underscores our clear commitment to Laupheim as well as to Germany and Europe as leading biotech hubs.”
Benedikt von Braunmühl, CEO of Rentschler Biopharma
Christiane Bardroff, COO of Rentschler Biopharma, added: “As a CDMO, it is our responsibility to support our global clients in transforming innovative ideas into life-saving biopharmaceuticals and enabling rapid market access for new therapies. With the new buffer media facility, we will be even better positioned to fulfill this responsibility, providing employees with a state-of-the-art working environment and enhanced operational efficiency.”
